WallStSmart

InMed Pharmaceuticals Inc (INM)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 350222% more annual revenue ($17.32B vs $4.94M). TEVA leads profitability with a 4.1% profit margin vs -172.2%. TEVA earns a higher WallStSmart Score of 47/100 (D+).

INM

Avoid

32

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -6.91

TEVA

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 5.0Value: 4.3Quality: 3.5
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INM2 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

TEVA1 strengths · Avg: 10.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

Areas to Watch

INM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.80M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-143.8%2/10

ROE of -143.8% — below average capital efficiency

Revenue GrowthGrowth
-26.2%2/10

Revenue declined 26.2%

TEVA4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

P/E RatioValuation
63.2x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : INM

The strongest argument for INM centers on Price/Book, Debt/Equity.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth. PEG of 1.04 suggests the stock is reasonably priced for its growth.

Bear Case : INM

The primary concerns for INM are EPS Growth, Market Cap, Return on Equity.

Bear Case : TEVA

The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 63.2x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.

Key Dynamics to Monitor

INM profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

INM carries more volatility with a beta of 0.98 — expect wider price swings.

TEVA is growing revenue faster at -0.8% — sustainability is the question.

TEVA generates stronger free cash flow (307M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (47/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InMed Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?